Ophthalmology

Intravitreal anti-VEGF use not tied to systemic adverse events

(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic ...

Ophthalmology

Repeated ranibizumab doesn't impair macular perfusion

(HealthDay)—For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.

Ophthalmology

Persistent DME more likely with bevacizumab treatment

(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.

Ophthalmology

Combo Tx superior for polypoidal choroidal vasculopathy

(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according ...

Diseases, Conditions, Syndromes

Bevacizumab safe for use in Tx of macular degeneration

(HealthDay)—The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD), according to research published online Sept. 15 ...

Medications

Aflibercept in AMD: No proof of added benefit

It is not proven that patients with wet age-related macular degeneration benefit from the new drug aflibercept, as the drug manufacturer did not present any suitable data for a comparison with the current standard therapy ...

Ophthalmology

Ranibizumab no better than saline for vitreous hemorrhage

(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, ...

page 1 from 2